Trials / Completed
CompletedNCT01449747
Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus
Mechanism of Reduced Response to DPP-4 Inhibitor in Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- The Catholic University of Korea · Academic / Other
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to confirm the mechanism of reduced response to DPP-4 inhibitor in some patients with type 2 diabetes and evaluate appropriate patients to treat with DPP-4 inhibitor
Detailed description
Sitagliptin, a DPP-4 inhibitor was used as an incretin enhancer in clinical practice first. In clinical trials, sitagliptin showed effective control of blood glucose level in type 2 diabetes and 100 mg once daily with metformin was similar to sulfonylurea (glipizide) with metformin in lowering HbA1c. Mostly in practice, stable blood glucose levels were maintained after change of sulfonylurea to sitagliptin in type 2 diabetes treatment. However, in some cases, there were abrupt severe hyperglycemia and uncontrolled blood glucose level after drug change to sitagliptin. Several mechanism could be considered for reduced response to DPP-4 inhibitor in some type 2 diabetes patients. Firstly, significantly reduced secretion of glucagon-like peptide 1 (GLP-1) more than expected in diabetes or functional defect of GLP-1 activity could be the mechanism of loss of GLP-1 effect irrespective of DPP-4. Secondly, mutation or functional defect of DPP-4 enzyme could not be inhibited by DPP-4 inhibitor. Thirdly, GLP-1 receptor mutation or other defect in β-cell responsiveness to GLP-1 leads to reduction of response to DPP-4 inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sitagliptin | Sitagliptin (100mg, per oral) once a day. |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2014-08-01
- Completion
- 2015-07-01
- First posted
- 2011-10-10
- Last updated
- 2015-12-14
- Results posted
- 2015-12-14
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01449747. Inclusion in this directory is not an endorsement.